Survival and mortality among users and non-users of hydroxyurea with sickle cell disease

• Main Authors: Olinda Maria Rodrigues de Araujo (Author), Maria Lúcia Ivo (Author), Marcos Antonio Ferreira Júnior (Author), Elenir Rose Jardim Cury Pontes (Author), Ieda Maria Gonçalves Pacce Bispo (Author), Eveny Cristine Luna de Oliveira (Author)
• Format: Book
• Published: Universidade de São Paulo, 2015-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

OBJECTIVE: to estimate survival, mortality and cause of death among users or not of hydroxyurea with sickle cell disease.METHOD: cohort study with retrospective data collection, from 1980 to 2010 of patients receiving inpatient treatment in two Brazilian public hospitals. The survival probability was determined using the Kaplan-Meier estimator, survival calculations (SPSS version 10.0), comparison between survival curves, using the log rank method. The level of significance was p=0.05.RESULTS: of 63 patients, 87% had sickle cell anemia, with 39 using hydroxyurea, with a mean time of use of the drug of 20.0±10.0 years and a mean dose of 17.37±5.4 to 20.94±7.2 mg/kg/day, raising the fetal hemoglobin. In the comparison between those using hydroxyurea and those not, the survival curve was greater among the users (p=0.014). A total of 10 deaths occurred, with a mean age of 28.1 years old, and with Acute Respiratory Failure as the main cause.CONCLUSION: the survival curve is greater among the users of hydroxyurea. The results indicate the importance of the nurse incorporating therapeutic advances of hydroxyurea in her care actions.

Item Description

1518-8345
10.1590/0104-1169.3385.2526